Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

Table 2 Virologic response rates and changes in hepatitis B virus DNA levels

Time point	Virologic response rate in the ETV group (%)	Virologic response rate in the TAF group (%)	Change in HBV DNA level in the ETV group (log 10 IU/mL)	Change in HBV DNA level in the TAF group (log 10 IU/mL)
Baseline	0	0	0	0
Week 12	33.3	53.3	-1.8	-2.6
Week 24	50	76.7	-2.2	-3.2
Week 36	60	86.7	-2.4	-3.6
Week 48	66.7	93.3	-2.4	-3.8

ETV: Entecavir; TAF: Tenofovir alafenamide; HBV: Hepatitis B virus.